Recurrent Non-small Cell Lung Cancer Withdrawn Phase 2 Trials for Erlotinib (DB00530)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01928160Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or GefitinibTreatment